Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary

Table 4 Cervical cancers attributable to different types of HPV and protection against 6-month persistent infections by the AS04-adjuvanted bivalent vaccine

HPV type	Cervical cancers attributable to the type (%)	Vaccine efficacy (%)	Vaccine efficacy against oncogenic infection (%)
HPV type	Cervical cancers attributable to the type (%)	Vaccine efficacy (%)	Without cross-protection	With cross-protection
16	65.4	94.3	67.42	75.33
18	6.1	94.3	67.42
33	5.6	45.1
31	4.1	77.5
45	2.9	76.1

ISSN: 1471-2458